DAUNORUBICIN HYDROCHLORIDE

Post-LOE

daunorubicin hydrochloride

Thayer Medical

ANDAINJECTIONINJECTABLE

Approved

Jan 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DAUNORUBICIN HYDROCHLORIDE (daunorubicin hydrochloride) by Thayer Medical is mechanism of action daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Approved for leukemia. First approved in 2000.

Drug data last refreshed 19h ago

Mechanism of Action

Mechanism of Action Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the…

Indications (1)

leukemia

Company

Worked on DAUNORUBICIN HYDROCHLORIDE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.